Phase I Trial of Recombinant Zoster Vaccine Initiated for Adults 40+
A Phase I clinical trial is underway to assess the safety and tolerability of a recombinant herpes zoster vaccine in adults aged 40 and older.
Phase I
Infectious Disease / Vaccine
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Positive results may support further development and potential market entry, influencing strategic positioning in the vaccine market.
Why it matters
The initiation of Phase I trial for a recombinant herpes zoster vaccine is significant as it may alter the competitive dynamics in the shingles vaccine market. Positive trial outcomes could lead to further development and market entry, challenging established products like Shingrix.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for safety data and tolerability outcomes, as well as subsequent phases of development.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.